"know who received placebo and who received treatment"
I'm certain they know this as well. How could they not? They are just shipping both and tossing the one they don't use in the trash, would kind of make it hard to just "burn" the treatments when it can be used for the cross over if/when the placebo group progresses.
Something substantial has to happen before NWBO needs cash again. Woodford I don't believe will continue to fund the trial/NWBO being as "underwater" he is on his share purchases.
The only issue I have is the large veil of secrecy the company portrays. Never a CC, but a "investor conference" every other month claiming "generals of the immune system". Waste of time and money for a company with a phase 3 trial they can't talk about and a phase 1 where everything is already known.
I'm with you on this one.
I've had questions about this company for awhile only for it to be more confirmed lately.
There is no way BABA pulls the numbers it does being a "pass thru" and they don't have the people/staff or infrastructure to purchase, house and ship the volume they claim.
Then MA stating a weaker outlook this quarter, also stating how the slowdown doesn't matter as "Chinese people are big savers" then a blow out quarter selling "fakes". Doesn't add up to me.
Seems they are doing some Valeant accounting as they seem to make a large acquisition every quarter and rolling that into financials.
I guess I want to add that what has me puzzled is the 75% review only 6 months or so later than the 50% review. Again, if the trial enrolled faster than linear, the 75% wouldn't be a big deal and actually would be a good sign I think.
Just wondering what your thoughts are on Rindopepimut?
I'm not sure what the randomization of those in the trial are, but I'm assuming 1 to 1.
Does 6 months seem reasonable for another 25% of events to occur? (given also that 75% have relapsed or worse yet died) when this happens
Median time to progression is 15.2 months for ACT ll.
Considering the trial started late 2011 and not knowing exact dates/enrollement (fully enrolled Jan 2015).
Anyone know the likely hood of 25% more events in 6 months and a "best guess" at meeting endpoints?
Just using rough numbers and linear enrollment.
Nov 2011 trial started.
May 2013 half should be enrolled
Nov 2014 fully enrolled.
So half should be enrolled by mid 2013 and 50% "events" was May 2015.
Now assuming 50% enrollment at May 2013 and first review at 50% of events at MAY 2015, 24 months later, it should be doing better than 15.2 months PFS...
I don't know and can't seem to find enrollment numbers, but if the trial enrolled faster than linear, this is really a good sign, if it enrolled slower, probably not such a good sign.
"I would go with your second observation."
I agree considering the obscene volume in puts purchased today, I'm guessing someone is unloading tomorrow.
Well then Blue, YOU should certainly buy some more HEB stock then!! HEB insiders are ditching 60 million shares for you to buy!! Sell everything you own and purchase HEB stock so you can rich like HEB insiders are (but they are millionaires from selling you stock)
A couple of quarters ago they said the same thing, then a couple of days later 200 million offering came out.. but at $24 bucks (ouch) at today's price.
Yep!! Pumping at it's finest!
Amazing what you can get people to write and publish when you toss a little coin their way!!
I can only assume ole Bill "I did not have sex with that woman" Ackman trying to get some of his millions back before he unload his position.
I've been guilty of pulling the trigger to late as well, I think we all have but this is getting a little far fetched on the lengths they are going trying to prop the stock price a bit.
It must just be for HEB's larger bagholders... I mean share holders that got this Email and it's probably from HEB pumping their latest CFS try with NIH.
Right, I'm sure this was a paid report by Ackman or some other hedge fund that is trying to unwind their rather large position and want someone else (retail specifically) to be the bag holders. .
While I agree that SOME of VRX drugs would be marketable, I can see offers to buy certain lines, but the company as it stands today is kryptonite to being bought do to it's aging drugs and, well, sales fraud along with MASSIVE debt.
"that don't care who they kill by delaying trials and stealing money off of company's?'
Surely you are talking about HEB's MGT that has successfully become MILLIONAIRES from working at HEB an siphoning off the cash they raise from newly issued stock sales!
"cause he died"
Did he die from taking Ampligen or not taking Ampligen is the question since Ampligen is the cure for everything according to DR Carter!
"ceo michael pearson has said co. is well positioned for growth"
Of course it is!! Once the Lawsuits, GOVT investigation and fraud charges are settled, not to mention those who are holding the 30 billion + DEBT notes (
Funny how this "Noble Prize Winner" stopped working with Ampligen and went on to more promising drugs!
Even the Noble Prize Winner couldn't find a clinical use for Ampligen, just like HEB's failed trials with Flumist (ongoing for 3 years with 25 enrolled, it will fail which is why it's been put on a shelf), Tamiflu, Breast Cancer, Ovarian Cancer, CFS just to name a few.
Even more highlights:
Until we undertake the end-of-review conference(s) with the FDA, we are unable to reasonably estimate the nature, costs, necessary efforts to obtain FDA clearance or anticipated completion dates of any additional clinical study or studies
Revenues from our Ampligen® Cost Recovery Program were $47,000 and $36,000 for the three months ended June 30, 2015 and 2014
offset by a decrease in clinical trial costs of $122,000 associated with the conclusion of our University of Washington study in 2014 utilizing Ampligen® as an adjuvant in optimally treated breast cancer patients as data from these patients was evaluated and resources were directed to other projects
The primary reason for this increase in 2015 was due to the payout of 2014 executive incentive bonuses for approximately $1,831,000 reflected in accrued expenses
We may issue shares to be used to meet our capital requirements or use shares to compensate employees, consultants and/or Directors. In this regard, we have registered $150,000,000 of securities for public sale pursuant to a universal shelf registration statement and we have been selling shares under this shelf registration statement and the EDA with Maxim. Through June 30, 2015, we had sold an aggregate of approximately 104,505,454 shares under the EDA.
so Bones... Why do you post extremely old news? Is it so you can try to fool naïve investors into believing HEB has something of value so HEB insiders can ditch newly issued company stock for CASH?
Why do you post extremely old news? Is it so you can try to fool naïve investors into believing HEB has something of value so HEB insiders can ditch newly issued company stock for CASH?
I've heard that a Nobel Prize winner drove a Ford Pinto at one time, I don't believe that makes the car any better.
Just because he "worked" with Ampligen doesn't mean it's worth anything. The bigger question is, why did he STOP working with Ampligen?